Overcoming Barriers to Recruiting Blacks/African-Americans for Dementia Research

6 September 2017

Eseosa Ighodaro

Paper in the Journal of Alzheimer's Disease exhorts fellow scientists to make changes to encourage minority participation in research

Lexington, KY - In a paper published in the Journal of Alzheimer's Disease, lead author Eseosa Ighodaro, PhD, encouraged fellow researchers to address the challenges associated with studying dementia in Blacks/African-Americans.

The paper, co-authored by researchers at the University of Kentucky's Sanders-Brown Center on Aging, the University of Washington, Rice University, and Rush University Medical Center, is a clear-eyed look at the barriers that hinder minority recruitment for dementia research and the misconceptions that potentially distort research outcomes through unintended bias.

"This study helps to identify problems in dementia-related research that are both historical and ongoing," said Peter Nelson, PM, PhD, of the Sanders-Brown Center on Aging. "You cannot seek solutions effectively until you are forthright about the problems."

Perhaps the paper's most provocative point is that using race as a variable in research can result in inaccurate data interpretation. The authors point to several studies exploring genetic ancestral markers and race self-identification to demonstrate that race is not a dependable proxy for genetics.

"Race is, in many senses, a social construct that evolves over time due to social policy, cultural beliefs, and political practices, and risks misinterpretation of the differences between individuals who identify with certain racial/ethnic groups," Ighodaro said.

Instead, she suggested that socioeconomic status variables such as zip code, income level, education, access to medical care, and other social determinants of health need to be included in data interpretation, pointing to two recent studies that demonstrated socioeconomic conditions were a better predictor of stroke risk and dementia than race.

Ighodaro also outlines horrific and unethical biomedical experimentation on African-Americans that continued into this century as one of the culprits for the African-American community's persistent mistrust of physicians and scientists. As a result, some African-Americans, who fear they are "guinea pigs," are less likely to participate in research or donate blood or other biospecimens, which can decrease Black/African-American representation in dementia research studies.

Furthermore, the paper asserts, there is a need for efforts to increase the "diversity of thought and identity" among scientists, which studies show will enhance the quality and output of research collaborations.

"Scientists need to think holistically about the determinants of health when studying underserved populations and break out of the conventional and erroneous mindset that genetics are the sole cause of health disparities," Ighodaro said, "and we must acknowledge and address the historical horrific mistreatment of Blacks/African Americans in biomedical research as a first step towards improved minority research recruitment."

"These barriers to what's called 'better science' won't be easily abated, but they are critically necessary to align the quality of our data with all the populations we serve – minority or otherwise."

Ighodaro ET, Nelson PT, Kukull WA, Schmitt FA, Abner EL, Caban-Holt A, Bardach SH, Hord DC, Glover CM, Jicha GA, Van Eldik LJ, Byrd AX, Fernander A (2017) Challenges and considerations related to studying dementia in Blacks/African Americans. J Alzheimers Dis 60, 1-10.

Contact:
Name: Laura C. Dawahare
Tel.: 859.257.5307
Email: Laura.dawahare@uky.edu

ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer's Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 4.151 according to Thomson Reuters' 2014 Journal Citation Reports. The Journal is published by IOS Press (www.iospress.com).